相关实验视频

Updated: Jun 3, 2025

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

一个二次性于波纳替尼的皮特里亚斯皮拉皮拉斯病例

Ariana Nateghi¹, Florence Lagacé-Thomassin², Julie Desrochers³

¹Department of Dermatology, Sherbrooke University, Sherbrooke, QC, Canada.

SAGE open medical case reports

|January 9, 2025

概括

一种白血病药物ponatinib可以引起罕见的皮肤反应. 这种病例显示了类似于pityriasis rubra pilaris的喷发,随着剂量调整而改善,突出显示了在癌症治疗期间需要管理副作用的必要性.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

波纳替尼 (Ponatinib) 是一种用于慢性髓性白血病和急性淋巴细胞白血病的氨酸激酶抑制剂.
罕见的皮肤副作用与ponatinib治疗有关.
像皮病 (Pityriasis rubra pilaris) (PRP) 这样的喷发是一种不常见的皮肤病症状.

研究的目的:

报告一例与波纳提尼布治疗相关的二次性皮疹状皮疹.
讨论在接受癌症治疗的患者中对剂量依赖性皮肤副作用的管理.
强调平衡瘤治疗疗效与皮肤毒性的重要性.

主要方法:

一个63岁的女性患者用ponatinib治疗的案例研究.
皮肤反应发展和进展的临床观察.
对剂量修改和局部治疗的治疗反应的评估.

主要成果:

患者在开始服用波纳提尼布后一个月出现了类似于皮特里亚斯皮拉里斯的喷发.
皮肤反应在减少波纳提尼布剂量后有所改善.
在较低的波纳提尼布剂量下观察到更轻微的喷发复发,用局部药物管理.

结论:

减少波纳替尼的剂量可以有效地管理药物诱导的皮肤副作用.
局部治疗包括特诺因,氨和软化剂可以提供症状缓解.
仔细管理剂量依赖性皮肤反应对于维持不间断的癌症治疗至关重要.

关键词:

案例报告案例报告费城染色体阳性的人.这种白血病是白血病.皮底里亚斯皮皮拉里斯 (rubra pilaris) 的情况波纳提尼布 (ponatinib) 是一种氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...